Evommune Inc. (EVMN) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 5 wire items for EVMN, including 2 analyst ratings, 1 press release or news item and 1 SEC filing. The most recent was published Oct 20, 2026.
Price$6.73+0.06 (+0.90%)
01:30 PM07:45 PM
News · 26 weeks46-50%
2026-05-032026-10-25
Mix1690d
- Other6(38%)
- SEC Filings6(38%)
- Analyst3(19%)
- Insider1(6%)
Latest news
25 items- ANALYSTMorgan Stanley resumed coverage on Evommune with a new price targetMorgan Stanley resumed coverage of Evommune with a rating of Overweight and set a new price target of $26.00
- INSIDERSEC Form 4 filed by Evommune Inc.4 - Evommune, Inc. (0002044725) (Issuer)
- ANALYSTUBS initiated coverage on Evommune with a new price targetUBS initiated coverage of Evommune with a rating of Neutral and set a new price target of $8.00
- SECEvommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology CongressPresentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces IL-18 inhibition as a novel, clinically relevant approach to treating atopic dermatitisBiomarker analyses confirm robust Th2 pathway modulation, as well as broad anti-inflammatory activity across multiple inflammatory pathways (Th1, Th17/22)Plan to initiate subcutaneous Phase 2b dose-ranging trial in mid-2027Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adu
- SECEvommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 CongressEvommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the upcoming European Academy of Dermatology & Venereology (EADV) Congress, taking place in Vienna, Austria from September 30 to October 3, 2026. EVO301 is a long-acting, native IL-18 binding protein (IL-18BP) fused to a serum albumin binding Fab, designed to neutralize aberrantly upregulated IL-18 activity. IL-18 sits upstream of the Th2 axis and mo
- SECEvommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis- Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated - EVO301, the Company’s IL-18BP fusion protein, advances as lead atopic dermatitis program following positive Phase 2a proof-of-concept data - Evommune to continue Phase 2b development of EVO756 in migraine prophylaxis Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial eva
- ANALYSTNeedham initiated coverage on Evommune with a new price targetNeedham initiated coverage of Evommune with a rating of Buy and set a new price target of $28.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Evommune Inc.SCHEDULE 13G/A - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form SCHEDULE 13G filed by Evommune Inc.SCHEDULE 13G - Evommune, Inc. (0002044725) (Subject)
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECSEC Form 10-Q filed by Evommune Inc.10-Q - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027 ‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference ‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline Evommune, Inc. (NYSE:EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 20
- SECEvommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
- PREvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis‑ MRGPRX2 receptor expressed in human trigeminal neurons and meningeal mast cells, the two key disease-relevant tissues in migraine biology ‑ EVO756 designed to inhibit three key neuropeptides (PACAP, VIP, Substance P) that trigger migraine signal through MRGPRX2 ‑ Top-line data expected in 2027 Evommune, Inc. (NYSE:EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO756, for the prophylactic treatment of migraine.
- SECSEC Form SCHEDULE 13G filed by Evommune Inc.SCHEDULE 13G - Evommune, Inc. (0002044725) (Subject)
- INSIDERChief Financial Officer Carver Kyle bought $13,260 worth of shares (1,000 units at $13.26), increasing direct ownership by 2% to 60,335 units (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- INSIDERDirector Kirsch Arthur S bought $133,000 worth of shares (10,000 units at $13.30) (SEC Form 4)4 - Evommune, Inc. (0002044725) (Issuer)
- ANALYSTEvommune downgraded by H.C. WainwrightH.C. Wainwright downgraded Evommune from Buy to Neutral
- ANALYSTEvommune downgraded by William BlairWilliam Blair downgraded Evommune from Outperform to Mkt Perform
- SECSEC Form 424B3 filed by Evommune Inc.424B3 - Evommune, Inc. (0002044725) (Filer)
- SECEvommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Evommune, Inc. (0002044725) (Filer)
EVMN FAQ
7 questionsWhat is the latest news on EVMN?
In the last 30 days Quantisnow tracked 5 wire items for EVMN: 2 analyst ratings, 1 press release or news item, 1 SEC filing and 1 insider trade. The most recent was published on October 20, 2026.Where does EVMN stock trade?
Evommune Inc. (EVMN) is listed on NYSE.What sector and industry is EVMN in?
Evommune Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Evommune Inc. go public?
Evommune Inc. (EVMN) completed its IPO in 2025.What are analysts saying about EVMN?
Evommune Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight with a $2600.00 price target on 2026-10-20.What companies are similar to EVMN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EVMN side-by-side with any of them on Quantisnow.How can I track EVMN on Quantisnow?
Quantisnow aggregates Evommune Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVMN to receive live email and push alerts on every new disclosure.